pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Repatha
drug
save

evolocumab

Marketedupdated 6mo ago
by $AMGN AMGEN INC
Approved
annual revenue · 2024–2024peak $2.4B
2024: $2.4B2024$2.4B
community read0 votes

indications

investigational
Hyperlipidemia

all catalysts(0)

nothing on the calendar yet

Trials studying evolocumab

  • phase4EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarctionactive not recruitingn=6,019
  • phase2YN001-004 in Patients With Coronary Atherosclerosis in Australiaterminatedn=3
  • phase1Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.recruitingn=400
  • phase2A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)active not recruitingn=10
  • EP1Mechanistic Clinical Trial of PCSK9 Inhibition for AAAnot yet recruitingn=44
  • phase4Lipid Management in Renal Transplant Recipients Using Evolocumab.completedn=81
  • phase1Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Doserecruitingn=400
  • phase4Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCIactive not recruitingn=2,166

News(10)

  • STAT+: Democrats begin asking: How far can we go on health care?
    Many in the party are pushing for Democratic lawmakers to go big on health care, but their dreams may crash into reality.
    stat · 8d ago
  • STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype
    Once again, a hot new technology that was supposed to speed up drug research has fallen flat.
    stat · 9d ago
  • STAT+: BIO joins the legal fight against Medicare pilot that ties drug prices to peer countries
    The model is a test of Trump's most-favored nation approach to drug pricing, though its impact is likely to be limited.
    stat · 9d ago
  • STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy
    Medical mystery at the AHA conference: A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke.
    stat · 9d ago
  • STAT+: Despite Novo drug’s failure, cardiologists say they will still pursue anti-inflammatories
    “These results, the fact that they're negative, does not invalidate that inflammation plays a very important role in cardiovascular disease."
    stat · 9d ago
  • STAT+: Democrats’ midterm landslide spells relief for hospitals
    Democrats are likely to focus on reversing Medicaid cuts and expanding insurance coverage, giving a boost to health care providers.
    stat · 10d ago
  • STAT+: New tumor cases show common gene therapy tool can come with risk
    New cases show AAV gene therapies like Zolgensma carry tumor risks, raising key concerns for SMA patients and gene therapy researchers in general.
    stat · 10d ago
  • Satellos' new Duchenne study endpoint; Amgen's Repatha cuts heart attack risk
    Plus, news about MetaVia, Agios Pharmaceuticals and Inovio. Satellos Bioscience changes Duchenne study primary endpoint: The company is studying a small-molecule drug called forazapadin aimed at he…
    endpoints · 10d ago
  • STAT+: Amgen’s Repatha linked to fewer heart attacks
    Pithy intro text about the biopharma milieu. Novartis cites more tumor reports after Zolgensma Novartis has disclosed seven previously unreported cases of tumors in children who received Zolgensma,…
    stat · 10d ago
  • STAT+: Beyond statins, one drug lowered heart attack risk by 20%
    A new study could help doctors figure out what medicine to prescribe for cholesterol when statins don't cut it: It's “answering a really challenging clinical question."
    stat · 11d ago
view all news mentions →
brand
Repatha
generic
evolocumab
indication
Atherosclerosis
phase
marketed
approved
2015-08-27
Data sources
openFDA · ClinicalTrials.gov
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?